BR112016018313A2 - moléculas de ligação multiespecíficas iga - Google Patents

moléculas de ligação multiespecíficas iga

Info

Publication number
BR112016018313A2
BR112016018313A2 BR112016018313A BR112016018313A BR112016018313A2 BR 112016018313 A2 BR112016018313 A2 BR 112016018313A2 BR 112016018313 A BR112016018313 A BR 112016018313A BR 112016018313 A BR112016018313 A BR 112016018313A BR 112016018313 A2 BR112016018313 A2 BR 112016018313A2
Authority
BR
Brazil
Prior art keywords
binding molecules
multispecific
iga binding
multispecific iga
relates
Prior art date
Application number
BR112016018313A
Other languages
English (en)
Other versions
BR112016018313A8 (pt
Inventor
Keyt Bruce
Zheng Fen
George Presta Leonard
F Carroll Stephen
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of BR112016018313A2 publication Critical patent/BR112016018313A2/pt
Publication of BR112016018313A8 publication Critical patent/BR112016018313A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção refere-se a moléculas de ligação multiespecíficas iga. em particular, a invenção refere-se a moléculas multiespecíficas, incluindo moléculas biespecíficas, de ligação que compreendem sequências de cadeia pesada de iga e métodos para a sua preparação e utilização.
BR112016018313A 2014-02-10 2015-02-10 Moléculas de ligação multiespecíficas iga BR112016018313A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461937984P 2014-02-10 2014-02-10
PCT/US2015/015268 WO2015120474A1 (en) 2014-02-10 2015-02-10 Iga multi-specific binding molecules

Publications (2)

Publication Number Publication Date
BR112016018313A2 true BR112016018313A2 (pt) 2017-10-10
BR112016018313A8 BR112016018313A8 (pt) 2018-06-12

Family

ID=52589796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018313A BR112016018313A8 (pt) 2014-02-10 2015-02-10 Moléculas de ligação multiespecíficas iga

Country Status (10)

Country Link
US (1) US10822399B2 (pt)
EP (1) EP3105250B1 (pt)
JP (1) JP2017512208A (pt)
KR (1) KR102378289B1 (pt)
CN (1) CN105992772A (pt)
AU (1) AU2015213593B2 (pt)
BR (1) BR112016018313A8 (pt)
CA (1) CA2939191C (pt)
DK (1) DK3105250T3 (pt)
WO (1) WO2015120474A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
PT3126383T (pt) 2014-04-03 2019-03-22 Igm Biosciences Inc Cadeia j modificada
AU2016209324B2 (en) 2015-01-20 2020-02-27 Igm Biosciences, Inc. Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
WO2016141303A2 (en) 2015-03-04 2016-09-09 Igm Biosciences, Inc. Cd20 binding molecules and uses thereof
CA2980751A1 (en) 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
MX2021004660A (es) * 2018-10-23 2021-05-28 Igm Biosciences Inc Moleculas de union multivalentes a base de igm- e iga-fc.
TW202202514A (zh) * 2020-03-23 2022-01-16 日商東興藥品工業股份有限公司 多聚體ＩｇＡ抗體之製造法及多重特異性多聚體ＩｇＡ抗體
JP2023552220A (ja) * 2020-12-03 2023-12-14 ザイムワークス ビーシー インコーポレイテッド ヘテロ二量体ＩｇＡ Ｆｃ構築物及びその使用の方法
WO2023196995A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH0775478B2 (ja) 1987-05-20 1995-08-09 三菱電機株式会社 交流エレベ−タ制御装置
EP0530216A4 (en) 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CN101014620B (zh) 2004-02-06 2012-05-09 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
US8377435B2 (en) 2004-11-05 2013-02-19 The Board Of Trustees Of The Leland Stanford Junior University Antibody induced cell membrane wounding
EP1933883B1 (en) 2005-08-03 2015-10-07 Rq Bioscience, Inc. Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
AU2008316703B2 (en) * 2007-10-25 2012-09-27 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
PE20091449A1 (es) * 2007-12-11 2009-10-07 Glaxo Group Ltd Proteinas de union a antigenos
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
DE102009020304A1 (de) 2009-05-07 2010-11-25 Hastem-Müller, Stefan Glied für ein Gliederband
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
CN102958539B (zh) * 2010-03-26 2015-07-01 泼莫纳搜索有限公司 能够识别血凝素干区上的杂亚型中和表位的IgG同种型全长免疫球蛋白和其作为抗-流感药物的应用
EP2560683B2 (en) * 2010-04-23 2022-07-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins
CN103429260B (zh) 2010-10-19 2016-08-10 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
IN2013MN01438A (pt) * 2011-03-17 2015-06-12 Univ Ramot
IN2014CN00953A (pt) 2011-07-14 2015-04-10 Crucell Holland Bv
PT2773671T (pt) * 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
DK3041862T3 (da) 2013-09-05 2020-07-27 Igm Biosciences Inc Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
PT3126383T (pt) 2014-04-03 2019-03-22 Igm Biosciences Inc Cadeia j modificada
AU2016209324B2 (en) 2015-01-20 2020-02-27 Igm Biosciences, Inc. Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
WO2016141303A2 (en) 2015-03-04 2016-09-09 Igm Biosciences, Inc. Cd20 binding molecules and uses thereof
CA2980751A1 (en) 2015-03-25 2016-09-29 Stephen F. Carroll Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
CN109562165A (zh) 2016-07-20 2019-04-02 Igm生物科学股份有限公司 多聚ox40结合分子及其用途
CA3030640A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
WO2018017889A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
JP7358365B2 (ja) 2018-02-26 2023-10-10 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
MX2021004660A (es) 2018-10-23 2021-05-28 Igm Biosciences Inc Moleculas de union multivalentes a base de igm- e iga-fc.
WO2020163646A1 (en) 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof

Also Published As

Publication number Publication date
CA2939191A1 (en) 2015-08-13
AU2015213593B2 (en) 2020-09-03
KR102378289B1 (ko) 2022-03-23
KR20160119196A (ko) 2016-10-12
JP2017512208A (ja) 2017-05-18
EP3105250B1 (en) 2020-08-05
WO2015120474A1 (en) 2015-08-13
US10822399B2 (en) 2020-11-03
DK3105250T3 (da) 2020-09-28
CA2939191C (en) 2023-04-04
AU2015213593A1 (en) 2016-08-25
CN105992772A (zh) 2016-10-05
EP3105250A1 (en) 2016-12-21
US20160368971A1 (en) 2016-12-22
BR112016018313A8 (pt) 2018-06-12

Similar Documents

Publication Publication Date Title
BR112016018313A2 (pt) moléculas de ligação multiespecíficas iga
HUS2300033I1 (hu) Bispecifikus, T-sejt-aktiváló antigénkötõ molekulák
HK1254966A1 (zh) 雙特異性抗cd19xcd3 t細胞活化性抗原結合份子
HK1252856A1 (zh) 雙特異性抗ceaxcd3 t細胞活化性抗原結合分子
HK1254068A1 (zh) 雙特異性t細胞活化性抗原結合分子
CL2018000778A1 (es) Proteínas de unión a pd-1 y métodos para usarlas
ZA201701341B (en) Bispecific her2 and cd3 binding molecules
ECSP17029218A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
HK1252791A1 (zh) 具有經修飾的j鏈的結合分子
DK3356401T3 (da) Bindingsmolekyler med modificeret j-kæde
HK1250737A1 (zh) 結合cd79的抗體分子
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
DK3177646T3 (da) Cd3-bindingsdomæne
EP3114240A4 (en) Methods using randomer-containing synthetic molecules
PL3200822T3 (pl) Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171)
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
GB201522391D0 (en) Antibody molecules
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
BR112016029236A2 (pt) métodos para tratar prurido.
PT3608337T (pt) Moléculas de ligação ao antigénio biespecíficas para ativação das células t
BR112016030237A2 (pt) Parceiros de ligação específicos para epímeros de vitamina d em ensaios de vitamina d
CL2015003308S1 (es) Señalizador para bicicletas.
TH1601003047A (th) ชิ้นส่วนแผ่นเหล็กกล้าขึ้นรูปร้อนและวิธีการผลิตมันและแผ่นเหล็กกล้าสำหรับ ขึ้นรูปร้อน
TH1501007271A (th) แผ่นเหล็กกล้าสำหรับสายพานเหล็กกล้า และกรรมวิธีสำหรับการผลิตสิ่งเดียวกัน, และสายพานเหล็กกล้า

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2460 DE 27/02/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: IGM BIOSCIENCES A/S (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B25A Requested transfer of rights approved

Owner name: IGM BIOSCIENCES, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.